Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 16037379 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Knowlden JM, et al. (2005) Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor. Endocrinology 146, 4609-18 16037379
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

Y869-p - EGFR (human)
Orthologous residues
EGFR (human): Y869‑p, EGFR iso5 (human): Y869‑p, EGFR (mouse): Y871‑p, EGFR (rat): Y870‑p, EGFR (pig): Y869‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody
 Relevant cell lines - cell types - tissues:  MCF-7 (breast cell), T47D (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IGF-2 increase
AG1024 IGF-2 inhibit treatment-induced increase
SU6656 IGF-2 inhibit treatment-induced increase
anti-IGF-2 IGF-2 inhibit treatment-induced increase
anti-IGF-2 decrease
TGF-alpha increase
SU6656 TGF-alpha inhibit treatment-induced increase
Downstream Regulation
 Effect of modification (function):  enzymatic activity, induced

Y1092-p - EGFR (human)
Orthologous residues
EGFR (human): Y1092‑p, EGFR iso5 (human): , EGFR (mouse): Y1092‑p, EGFR (rat): Y1091‑p, EGFR (pig): Y1091‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody
 Relevant cell lines - cell types - tissues:  MCF-7 (breast cell), T47D (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
IGF-2 increase
AG1024 IGF-2 inhibit treatment-induced increase
SU6656 IGF-2 inhibit treatment-induced increase
anti-IGF-2 IGF-2 inhibit treatment-induced increase
anti-IGF-2 decrease
TGF-alpha increase
SU6656 TGF-alpha inhibit treatment-induced increase
Downstream Regulation
 Effect of modification (function):  enzymatic activity, induced

Y1161-p - IGF1R (human)
Orthologous residues
IGF1R (human): Y1161‑p, IGF1R (mouse): Y1163‑p, IGF1R (rat): Y1162‑p, IGF1R (pig): Y1161‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody
 Relevant cell lines - cell types - tissues:  MCF-7 (breast cell), T47D (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IGF-2 increase
AG1024 IGF-2 inhibit treatment-induced increase
anti-IGF-2 IGF-2 inhibit treatment-induced increase
AG1024 decrease
anti-IGF-2 decrease
Downstream Regulation
 Effect of modification (function):  enzymatic activity, induced, molecular association, regulation
 Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
Src (human) Induces phosphorylation co-immunoprecipitation, electrophoretic visualization

Y1346-p - IGF1R (human)
Orthologous residues
IGF1R (human): Y1346‑p, IGF1R (mouse): Y1352‑p, IGF1R (rat): Y1349‑p, IGF1R (pig): Y1346‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody
 Relevant cell lines - cell types - tissues:  MCF-7 (breast cell), T47D (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IGF-2 increase
AG1024 IGF-2 inhibit treatment-induced increase
anti-IGF-2 IGF-2 inhibit treatment-induced increase
AG1024 decrease
anti-IGF-2 decrease
Downstream Regulation
 Effect of modification (function):  enzymatic activity, induced, molecular association, regulation
 Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
Src (human) Induces phosphorylation co-immunoprecipitation, electrophoretic visualization

Y419-p - Src (human)
Orthologous residues
Src (human): Y419‑p, Src (mouse): Y424‑p, Src iso2 (mouse): Y418‑p, Src (rat): Y419‑p, Src (chicken): Y416‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody
 Relevant cell lines - cell types - tissues:  MCF-7 (breast cell), T47D (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IGF-2 increase
AG1024 IGF-2 inhibit treatment-induced increase
SU6656 IGF-2 inhibit treatment-induced increase
anti-IGF-2 IGF-2 inhibit treatment-induced increase
anti-IGF-2 decrease
TGF-alpha increase
SU6656 TGF-alpha inhibit treatment-induced increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.